Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Agnoletto

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|August 22, 2022
Mitochondria dysfunction in circulating tumor cellsChiara Agnoletto, Stefano Volinia
Cancers|June 2, 2021
Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical PracticeChiara Agnoletto, Chiara Caruso, Cecilia Garofalo
International Journal of Molecular Sciences|March 29, 2023
Exosome-Based Liquid Biopsy Approaches in Bone and Soft Tissue Sarcomas: Review of the Literature, Prospectives, and Hopes for Clinical ApplicationChiara Agnoletto, Ymera Pignochino, Chiara Caruso, et al.
High-Throughput|November 21, 2018
SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?Linda Minotti, Chiara Agnoletto, Federica Baldassari, et al.
Frontiers in Oncology|September 14, 2018
The Network of Non-coding RNAs in Cancer Drug ResistanceFabio Corrà, Chiara Agnoletto, Linda Minotti, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Molecular Cancer|March 20, 2020
The network of non-coding RNAs and their molecular targets in breast cancerFrancesca Crudele, Nicoletta Bianchi, Eva Reali, et al.
Cytokine|June 1, 2013
The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newbornsGiorgio Zauli, Lorenzo Monasta, Liza Vecchi Brumatti, et al.
Acta Diabetologica|August 9, 2013
The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirementGianluca Tornese, Dario Iafusco, Lorenzo Monasta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2013
C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathwayPaola Secchiero, Erika Rimondi, Maria Grazia di Iasio, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|August 22, 2022
Mitochondria dysfunction in circulating tumor cellsChiara Agnoletto, Stefano Volinia
Cancers|June 2, 2021
Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical PracticeChiara Agnoletto, Chiara Caruso, Cecilia Garofalo
International Journal of Molecular Sciences|March 29, 2023
Exosome-Based Liquid Biopsy Approaches in Bone and Soft Tissue Sarcomas: Review of the Literature, Prospectives, and Hopes for Clinical ApplicationChiara Agnoletto, Ymera Pignochino, Chiara Caruso, et al.
High-Throughput|November 21, 2018
SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?Linda Minotti, Chiara Agnoletto, Federica Baldassari, et al.
Frontiers in Oncology|September 14, 2018
The Network of Non-coding RNAs in Cancer Drug ResistanceFabio Corrà, Chiara Agnoletto, Linda Minotti, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Molecular Cancer|March 20, 2020
The network of non-coding RNAs and their molecular targets in breast cancerFrancesca Crudele, Nicoletta Bianchi, Eva Reali, et al.
Cytokine|June 1, 2013
The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newbornsGiorgio Zauli, Lorenzo Monasta, Liza Vecchi Brumatti, et al.
Acta Diabetologica|August 9, 2013
The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirementGianluca Tornese, Dario Iafusco, Lorenzo Monasta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2013
C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathwayPaola Secchiero, Erika Rimondi, Maria Grazia di Iasio, et al.
Pageof 3